Krystal Biotech Inc. Reports Strong Q2 2025 Results, Highlights Growth in Genetic Medicine
Pittsburgh, PA — Krystal Biotech Inc. (NASDAQ: KRYS), a prominent player in the biotechnology landscape, has reported impressive financial results for the second quarter of 2025, showcasing significant growth driven by its flagship product, VYJUVEK. The company continues its commitment to developing groundbreaking genetic therapies aimed at treating rare diseases, with an increasing focus on expanding its product pipeline and market reach.
1. Financial Performance Overview
Revenue Surge
For the three months ending June 30, 2025, Krystal Biotech recorded total product revenue of $96.0 million, a notable increase from $70.3 million in the same quarter of the previous year. This growth can be primarily attributed to the strong demand for VYJUVEK, which is now approved in multiple regions, including the U.S., Europe, and Japan.
The company's gross margin remains robust at 93%, underscoring its operational efficiency and the premium nature of its gene therapy products.
Income Statement Highlights
Krystal Biotech's net income for Q2 2025 was $38.33 million, reflecting a substantial increase from $15.56 million in Q2 2024. Operating income also saw a significant rise to $39.30 million, driven by a carefully managed cost structure, despite a rise in selling, general, and administrative expenses, which increased by $7.5 million due to heightened marketing efforts.
| Aug 2024 | Aug 2025 | |
|---|---|---|
Net Income | 105.9M | 146.7M |
Profit | 105.9M | 146.7M |
Net Income Continuing | 105.9M | 146.7M |
Income Tax Expense | 2.44M | 22.02M |
Pretax Income | 108.3M | 168.7M |
Non-operating Income | 129.3M | 29.45M |
Operating Income | -20.97M | 139.2M |
Revenue | 166.2M | 359.2M |
Costs and Expenses | 187.2M | 219.9M |
Operating Expenses | 187.2M | 219.9M |
Research & Development | 48.53M | 55.69M |
Selling, General & Administrative | 102.1M | 127.8M |
Other Operating Expenses | 36.52M | 36.32M |
Balance Sheet Strength
As of June 30, 2025, Krystal Biotech's total assets reached $1.13 billion, a significant increase from $917.6 million reported a year prior. The company boasts a strong cash position with $681.9 million in cash and short-term investments, providing ample liquidity to support ongoing and future projects.
Liabilities were reported at $97.74 million, with total equity standing at $1.04 billion, indicating a solid capital structure that supports growth initiatives and operational stability.
| Aug 2024 | Aug 2025 | |
|---|---|---|
Total Assets | 917.6M | 1.13B |
Total Current Assets | 682.7M | 841.3M |
Cash and Equivalents | 345.7M | 353.8M |
Short-term Investments | 213.8M | 328.1M |
Net Inventories | 12.17M | 31.04M |
Accounts Receivable | 103.2M | 111.4M |
Prepaid Expenses | 7.74M | 16.88M |
Other Current Assets | 0 | 39K |
Total Non-current Assets | 234.8M | 297.0M |
Long-term Investments | 69.29M | 138.8M |
Net PP&E | 158.8M | 150.3M |
Lease Assets | 6.66M | 7.65M |
Other Non-current Assets | 126K | 197K |
Total Liabilities and Equity | 917.6M | 1.13B |
Total Liabilities | 78.76M | 97.74M |
Total Current Liabilities | 71.85M | 86.89M |
Accounts Payable and Accrued Liabilities | 5.42M | 7.12M |
Current Debt | 1.36M | 1.61M |
Other Current Liabilities | 65.06M | 78.15M |
Total Non-current Liabilities | 6.91M | 10.85M |
Other Non-current Liabilities | 6.91M | 10.85M |
Total Equity and Non-controlling Interests | 838.8M | 1.04B |
Total Equity | 838.8M | 1.04B |
2. VYJUVEK: A Game-Changer in Genetic Medicine
VYJUVEK (beremagene geperpavec-svdt), the first redosable gene therapy for Dystrophic Epidermolysis Bullosa (DEB), continues to be a cornerstone of Krystal Biotech's strategy. The therapy, approved in the U.S. in May 2023, received marketing authorization from the European Commission on April 23, 2025, and was approved in Japan on July 24, 2025.
As of the end of Q2 2025, cumulative net product revenue from VYJUVEK stands at $525.4 million, with a strong gross margin illustrating the product's market acceptance and the efficacy of Krystal's innovative manufacturing processes.
3. Expanding Pipeline and Strategic Developments
Advancements in Clinical Programs
Krystal Biotech continues to advance its pipeline with several promising candidates:
- KB407 for cystic fibrosis and KB408 for Alpha-1 Antitrypsin Deficiency are both showing progress in clinical trials, with positive safety data emerging from their respective Phase 1 studies.
- The company's efforts in ophthalmology are reflected in KB803 and KB801, targeting ocular complications in DEB and neurotrophic keratitis, respectively.
Strategic Leadership Changes
In an effort to bolster its aesthetics division, Krystal Biotech appointed Marc Forth as CEO of Jeune Aesthetics in April 2025 and welcomed Nishant Saxena as CFO in January 2025, indicating a strategic focus on expanding into aesthetic medicine, notably with the positive Phase 1 results for KB304.
4. Cash Flow and Future Outlook
Krystal Biotech reported a net cash change of $45.05 million for Q2 2025, indicating a healthy operational cash flow of $52.72 million. The company is committed to utilizing its cash reserves judiciously to fund ongoing research and development, while also exploring opportunities for additional capital to support its expansion.
| Aug 2024 | Aug 2025 | |
|---|---|---|
Net Change in Cash | 69.91M | 8.04M |
Effect of Exchange Rate Changes | -278K | 922K |
Net Cash from Operating Activities | -16.73M | 195.3M |
Operating Profit | 105.9M | 146.7M |
Adjustment to Operating Profit | -122.6M | 48.67M |
Net Cash from Investing Activities | 49.69M | -183.4M |
Investments | 44.28M | 173.8M |
Productive Assets | -93.98M | 9.52M |
Net Cash from Financing Activities | 37.22M | -4.87M |
Equity Issuance/Repurchase | 42.61M | 9.05M |
Other Financing Activities | -5.38M | -13.92M |
5. Conclusion
Krystal Biotech Inc. is well-positioned for continued growth as it leverages its innovative gene therapy platform and expands its product offerings. With strong financial results for Q2 2025, robust market demand for VYJUVEK, and an expanding pipeline, the company is set to make significant strides in both genetic medicine and aesthetic treatments. As it navigates the challenges of a rapidly evolving industry, Krystal remains focused on its mission to address unmet medical needs and improve patient outcomes globally.
